Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Results of a Prospective, Open-Label, Phase 4 Study Evaluating the Safety, Efficacy, and Treatment Satisfaction in Adult Immune Thrombocytopenia (ITP) Subjects after Switching to Avatrombopag from Eltrombopag or Romiplostim

Michael D Tarantino, Scott Kolodny, Jessica Zhang, Brian Jamieson, Michael Vredenburg

Blood (2024) 144 (Supplement 1): 2560.

https://doi.org/10.1182/blood-2024-205489

Published: 2024

Journal Articles

Enhanced Patient Satisfaction and Stability of Platelet Counts Following a Switch from Eltrombopag (ELT) or Romiplostim (ROMI) to Avatrombopag (AVA) in Adult Idiopathic Thrombocytopenic Purpura (ITP): Post-Hoc Analyses from a Prospective Phase 4 Study

Michael D Tarantino, Scott Kolodny, Michael Marrone, Brian Jamieson, Michael Vredenburg

Blood (2024) 144 (Supplement 1): 2559.

https://doi.org/10.1182/blood-2024-205466

Published: 2024

Journal Articles

Real-World Treatment Patterns and Outcomes in Patients with Primary Immune Thrombocytopenia Treated with Avatrombopag in the United States: Real-AVA 2.0 Interim Analysis Results

Srikanth Nagalla, Moshe Y. Levy, Shruti Chaturvedi, Scott Kolodny, Abiola Oladapo, Chelsea Bernheisel, Elyse Swallow, Debbie Goldschmidt, Ali Greatsinger, Kirthana Sarathy, Loren Ormenaj, Michael Vredenburg

Blood (2024) 144 (Supplement 1): 3700.

https://doi.org/10.1182/blood-2024-200320

Published: 2024

Journal Articles

Hematologic Improvement Experienced By Pacritinib-Treated Patients with Myelofibrosis in Real-World Clinical Settings

Michael Marrone, Lisa Morere, Abiola Oladapo, Purvi Suthar, Teena Sura, Anupama Vasudevan, Michael Vredenburg, Jia Zeng, Raajit Rampal, John O. Mascarenhas

Blood (2024) 144 (Supplement 1): 3814.

https://doi.org/10.1182/blood-2024-210826

Published: 2024

Journal Articles

Real-Word Effectiveness of Pacritinib in Patients with Myelofibrosis Who Have Thrombocytopenia and Anemia

Raajit Rampal, Michael Marrone, Lisa Morere, Abiola Oladapo, Purvi Suthar, Teena Sura, Anupama Vasudevan, Michael Vredenburg, Jia Zeng, John O. Mascarenhas

Blood (2024) 144 (Supplement 1): 6649.

https://doi.org/10.1182/blood-2024-210274

Published: 2024

Journal Articles

Early Anemia Response in Patients with Myelofibrosis Treated with Pacritinib in Real-Word Clinical Settings

John O. Mascarenhas, Michael Marrone, Lisa Morere, Abiola Oladapo, Purvi Suthar, Teena Sura, Anupama Vasudevan, Michael Vredenburg, Jia Zeng, Raajit Rampal

Blood (2024) 144 (Supplement 1): 6650.

https://doi.org/10.1182/blood-2024-210598

Published: 2024

Journal Articles

Interim Analysis of Platelet Response in a Prospective Phase 4 Study in Adult Immune Thrombocytopenia (ITP) Subjects after Switching from Eltrombopag (ELT) or Romiplostim (ROMI) to Avatrombopag (AVA)

Michael D. Tarantino, Scott Kolodny, Jessica Zhang, Brian Jamieson, Michael Vredenburg

Blood (2023) 142 (Supplement 1): 2577.

https://doi.org/10.1182/blood-2023-189908

Published: 2023

Journal Articles

Real-World Treatment Patterns and Outcomes in Patients with Immune Thrombocytopenia Treated with Avatrombopag in the United States: Real-AVA 2.0 Study Design

Srikanth Nagalla, Shruti Chaturvedi, Moshe Levy, Scott Kolodny, Abiola Oladapo, Chelsea Bernheisel, Brian Jamieson, Debbie Goldschmidt, Elyse Swallow, Ali Greatsinger, Michael Vredenburg

Blood (2023) 142 (Supplement 1): 5127.

https://doi.org/10.1182/blood-2023-189009

Published: 2023

Journal Articles

Interim Analysis of Treatment Satisfaction from a Prospective Phase 4 Study in Adult Immune Thrombocytopenia (ITP) Subjects after Switching from Eltrombopag or Romiplostim to Avatrombopag

Michael D. Tarantino, Scott Kolodny, Jessica Zhang, Brian Jamieson, Michael Vredenburg

Blood (2023) 142 (Supplement 1): 3954.

https://doi.org/10.1182/blood-2023-189224

Published: 2023

Journal Articles

Real-World Demographic and Clinical Characteristics of Patients Initiating Avatrombopag in the US: The Real-AVA Study

Scott Kolodny, Abiola Oladapo, Michael Vredenburg, Brian Jamieson, Elyse Swallow, Debbie Goldschmidt, Miriam L. Zichlin, Priscilla Lopez, Mikhail Davidson, John Yee

Blood (2022) 140 (Supplement 1): 13150–13151.

https://doi.org/10.1182/blood-2022-169369

Published: 2022

Journal Articles

Avatrombopag Treatment Response in Patients with Immune Thrombocytopenia: A Real-World Evidence Study

Abiola Oladapo, Scott Kolodny, Michael Vredenburg, Brian Jamieson, Elyse Swallow, Debbie Goldschmidt, Miriam L. Zichlin, Mikhail Davidson, Louise Yu, John Yee

Blood (2022) 140 (Supplement 1): 10889–10890.

https://doi.org/10.1182/blood-2022-169162

Published: 2022

Journal Articles

Durability of Platelet Response When Switching from Eltrombopag or Romiplostim to Avatrombopag in Immune Thrombocytopenia (ITP): A Multicenter Study

Hanny Al-Samkari, Debbie Jiang, Terry B. Gernsheimer, Howard A. Liebman, Susie Lee, Chelsea Bernheisel, Scott Kolodny, Matthew Wojdyla, Michael Vredenburg, Brian Jamieson, Adam Cuker

Blood (2021) 138 (Supplement 1): 1015.

https://doi.org/10.1182/blood-2021-151321

Published: 2021

Journal Articles

Consistent Efficacy Demonstrated By Avatrombopag in Immune Thrombocytopenia (ITP) Regardless of the Number of Lines of Prior ITP Treatment

Morey Blinder, MD, Michael Vredenburg, PhD, Wei Tian, PhD, Brian Jamieson, MDBA, Keith R McCrae, MD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-136585

Published: 2020

Journal Articles

Characterization of Thromboembolic Events Occurring during the Avatrombopag Immune Thrombocytopenia (ITP) Clinical Development Program

Caroline I. Piatek, MD, Brian Jamieson, MDBA, Michael Vredenburg, PhD

Blood (2020) 136 (Supplement 1): 39.

https://doi.org/10.1182/blood-2020-141273

Published: 2020

Journal Articles

Durability of Initial Platelet Count Response in Patients Treated with Avatrombopag for Immune Thrombocytopenia (ITP): Post-Hoc Results from a Phase 3 Clinical Study

Shivi Jain, MDMBBS, Matthew Wojdyla, PharmD, Michael Vredenburg, PhD, Brian Jamieson, MDBA, Terry B. Gernsheimer, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-142764

Published: 2020

Journal Articles

Efficacy Analyses from the Immune Thrombocytopenia (ITP) Clinical Development Program for Avatrombopag: Comparisons with Placebo and Eltrombopag

Michael D Tarantino, MD, Michael Vredenburg, PhD, Wei Tian, PhD, Brian Jamieson, MDBA, Kashyap B Patel, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-142788

Published: 2020

Journal Articles

Cost-Effectiveness of Avatrombopag for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease

Lee F. Allen, MD PhD, Kavita Aggarwal, PharmD, Michael Vredenburg, PhD, Christine Barnett, PhD, Deirdre Mladsi, BA, Ray Kim, MD

Blood (2019) 134 (Supplement_1): 3454.

https://doi.org/10.1182/blood-2019-131822

Published: 2019

Journal Articles

Long-Term Response Rates in Patients with Chronic Immune Thrombocytopenia Treated with Avatrombopag: Additional Analyses from a Phase 3 Study and Its Extension Phase

Hanny Al-Samkari, MD, Kavita Aggarwal, PharmD, Michael Vredenburg, PhD, Wei Tian, PhD, Lee F. Allen, MD PhD

Blood (2019) 134 (Supplement_1): 2356.

https://doi.org/10.1182/blood-2019-131215

Published: 2019

Journal Articles

The Burden of Disease and IMPACT of Immune Thrombocytopenia (ITP) on Patients: Results from an ITP Survey

James B. Bussel, MD, Alexandra Kruse, Caroline Kruse, Jody Shy, Kavita Aggarwal, PharmD, Michael Vredenburg, PhD, Keith R McCrae, MD

Blood (2019) 134 (Supplement_1): 1076.

https://doi.org/10.1182/blood-2019-131351

Published: 2019

Journal Articles

Platelet Response to Avatrombopag in Patients with Chronic Immune Thrombocytopenia: Additional Analyses from a Phase 3 Study and Its Extension

Srikanth Nagalla, MBBS,MS, Michael Vredenburg, PhD, Wei Tian, PhD, Lee F. Allen, MD PhD

Blood (2019) 134 (Supplement_1): 1071.

https://doi.org/10.1182/blood-2019-130963

Published: 2019

NARROW

Results of a Prospective, Open-Label, Phase 4 Study Evaluating the Safety, Efficacy, and Treatment Satisfaction in Adult Immune Thrombocytopenia (ITP) Subjects after Switching to Avatrombopag from Eltrombopag or Romiplostim

Enhanced Patient Satisfaction and Stability of Platelet Counts Following a Switch from Eltrombopag (ELT) or Romiplostim (ROMI) to Avatrombopag (AVA) in Adult Idiopathic Thrombocytopenic Purpura (ITP): Post-Hoc Analyses from a Prospective Phase 4 Study

Real-World Treatment Patterns and Outcomes in Patients with Primary Immune Thrombocytopenia Treated with Avatrombopag in the United States: Real-AVA 2.0 Interim Analysis Results

Hematologic Improvement Experienced By Pacritinib-Treated Patients with Myelofibrosis in Real-World Clinical Settings

Real-Word Effectiveness of Pacritinib in Patients with Myelofibrosis Who Have Thrombocytopenia and Anemia

Early Anemia Response in Patients with Myelofibrosis Treated with Pacritinib in Real-Word Clinical Settings

Interim Analysis of Platelet Response in a Prospective Phase 4 Study in Adult Immune Thrombocytopenia (ITP) Subjects after Switching from Eltrombopag (ELT) or Romiplostim (ROMI) to Avatrombopag (AVA)

Real-World Treatment Patterns and Outcomes in Patients with Immune Thrombocytopenia Treated with Avatrombopag in the United States: Real-AVA 2.0 Study Design

Interim Analysis of Treatment Satisfaction from a Prospective Phase 4 Study in Adult Immune Thrombocytopenia (ITP) Subjects after Switching from Eltrombopag or Romiplostim to Avatrombopag

Real-World Demographic and Clinical Characteristics of Patients Initiating Avatrombopag in the US: The Real-AVA Study

Avatrombopag Treatment Response in Patients with Immune Thrombocytopenia: A Real-World Evidence Study

Durability of Platelet Response When Switching from Eltrombopag or Romiplostim to Avatrombopag in Immune Thrombocytopenia (ITP): A Multicenter Study

Consistent Efficacy Demonstrated By Avatrombopag in Immune Thrombocytopenia (ITP) Regardless of the Number of Lines of Prior ITP Treatment

Characterization of Thromboembolic Events Occurring during the Avatrombopag Immune Thrombocytopenia (ITP) Clinical Development Program

Durability of Initial Platelet Count Response in Patients Treated with Avatrombopag for Immune Thrombocytopenia (ITP): Post-Hoc Results from a Phase 3 Clinical Study

Efficacy Analyses from the Immune Thrombocytopenia (ITP) Clinical Development Program for Avatrombopag: Comparisons with Placebo and Eltrombopag

Cost-Effectiveness of Avatrombopag for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease

Long-Term Response Rates in Patients with Chronic Immune Thrombocytopenia Treated with Avatrombopag: Additional Analyses from a Phase 3 Study and Its Extension Phase

The Burden of Disease and IMPACT of Immune Thrombocytopenia (ITP) on Patients: Results from an ITP Survey

Platelet Response to Avatrombopag in Patients with Chronic Immune Thrombocytopenia: Additional Analyses from a Phase 3 Study and Its Extension

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only